Bio-Rad Laboratories Inc (BIO) reports a 3.9% sales increase in Q4 2025, driven by diagnostics growth, despite supply chain and market headwinds.

Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...

Bio-Rad Laboratories, Inc. ( BIO) Q4 2025 Earnings Call February 12, 2026 5:00 PM EST Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this ...

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced the launch of the CFX Duet Real-Time PCR System to support researchers in ...

The Bio-Rad CFX Opus qPCR, equipped with a 96-well thermal block, is capable of detecting fluorescent signals across up to five channels. This ensures exceptional thermal uniformity and precise ...

ddPCR reportedly provides quantification of target molecules with unprecedented precision and sensitivity. Bio-Rad Laboratories purchased QuantaLife for $162 million in cash plus future milestone ...

On October 29, 2025, Bio-Rad Laboratories reported third-quarter earnings with sales of US$653 million and a net loss of US$341.9 million, while also completing a major share repurchase and announcing ...